In an adult with suspected gram‑negative bacillary meningitis, which aerobic gram‑negative bacilli are most common and what empiric antibiotic regimen should be initiated, including modifications for Pseudomonas risk or ESBL‑producing organisms?

Aerobic Gram-Negative Bacilli Causing Meningitis in Adults

Most Common Causative Organisms

In community-acquired gram-negative bacillary meningitis, Escherichia coli and Klebsiella pneumoniae are the predominant pathogens, while post-neurosurgical cases are most commonly caused by Enterobacter species, E. coli, Pseudomonas aeruginosa, and Acinetobacter species. 1, 2, 3

Community-Acquired Cases

• E. coli* and *K. pneumoniae account for the majority of spontaneous gram-negative bacillary meningitis in adults 3, 4
• K. pneumoniae is particularly associated with diabetes mellitus (44% of cases) and bacteremia (61% of cases) 3
• Community-acquired gram-negative meningitis carries extremely high mortality (72-83%) despite third-generation cephalosporin therapy 3

Nosocomial/Post-Neurosurgical Cases

• Enterobacter species (35%), E. coli (22.5%), and P. aeruginosa (15%) are the most frequent pathogens 2
• Serratia marcescens, Enterobacter cloacae, and Acinetobacter baumannii are also significant contributors 5
• External CSF drainage devices are the most important predisposing factor 3
• Recent neurosurgery (within 21 days median) and presence of neurosurgical devices account for 75-80% of cases 4, 5

---

Empiric Antibiotic Regimen

For suspected gram-negative bacillary meningitis, initiate vancomycin 15-20 mg/kg IV every 8-12 hours PLUS an anti-pseudomonal beta-lactam (cefepime 2g IV every 8 hours, ceftazidime 2g IV every 8 hours, or meropenem 2g IV every 8 hours) within 1 hour of presentation. 6, 7

Standard Empiric Coverage

• Vancomycin targets methicillin-resistant staphylococci (common co-pathogens in 20% of cases) 7, 4
• Anti-pseudomonal beta-lactam provides broad gram-negative coverage including Pseudomonas 7
• This regimen must be initiated immediately—delay is strongly associated with increased mortality 6

Critical Resistance Considerations

• 25-58% of gram-negative bacilli in nosocomial meningitis are resistant to third-generation cephalosporins 2, 5
• Third-generation cephalosporin resistance is an independent predictor of mortality (adjusted OR = 33.65) 5
• Enterobacter species can develop inducible resistance during cephalosporin therapy, necessitating carbapenem switch 1

---

Modifications for Specific Risk Factors

High Pseudomonas Risk (Post-Neurosurgical, External Drains)

• Combination therapy is mandatory: carbapenem (meropenem 2g IV every 8 hours) PLUS aminoglycoside (amikacin) or fluoroquinolone 7, 1
• Single-agent therapy for Pseudomonas is inadequate and associated with treatment failure 7
• Consider intraventricular antibiotics for refractory cases (recommended for 2-3 weeks combined with IV therapy) 2

ESBL-Producing Organisms

• Switch to carbapenem (meropenem 2g IV every 8 hours) when ESBL-producers are identified or suspected based on local epidemiology 1
• Approximately 50% of patients require regimen change from initial cephalosporin to carbapenem based on susceptibility results 1
• Initial empiric ceftriaxone plus amikacin, then tailoring to carbapenem, achieved 85% cure rate in one series 1

Community-Acquired with Bacteremia

• Maintain aggressive empiric coverage as above, recognizing that bacteremia, shock, and deep coma are adverse prognostic factors 3
• Blood cultures must be obtained before antibiotics but should not delay treatment beyond 1 hour 6

---

Treatment Duration and Monitoring

Treat for at least 14 days after the last positive CSF culture—this duration guarantees cure in appropriately treated patients. 1

• Median treatment duration is 19-21 days for gram-negative bacillary meningitis 1, 2
• Consider repeat CSF cultures to document sterilization in treatment-resistant cases 7
• Monitor vancomycin trough concentrations (target 15-20 mg/mL) and renal function 7
• No treatment failures occurred in patients receiving >12 days of appropriate therapy 1

---

Critical Pitfalls to Avoid

• Never use penicillin or ampicillin monotherapy for nosocomial meningitis—this is inappropriate due to high resistance rates 7
• Never use single-agent therapy for Pseudomonas infections—combination therapy is essential 7
• Never delay antibiotics for imaging or lumbar puncture—empiric treatment must begin within 1 hour of presentation 6
• Never assume third-generation cephalosporins are adequate in post-neurosurgical patients—25-58% resistance rates mandate broader coverage 2, 5
• Never underdose antibiotics—CSF penetration requires maximum recommended doses 7